Meeting
2021 ASCO Annual Meeting
Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs).
Authors
Andrew Scott Paulson
Texas Oncology/The US Oncology Network, Dallas, TX
Andrew Scott Paulson , Daneng Li , Max W. Sung , Christopher Tucci , John S. Kauh , Shivani Nanda , Marek K. Kania , Arvind Dasari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Clinical Trial Registration Number
NCT02549937
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4114)
DOI
10.1200/JCO.2021.39.15_suppl.4114
Abstract #
4114
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.
First Author: Arvind Dasari
Poster
2022 ASCO Annual Meeting
A pooled analysis of surufatinib safety from phase 3 trials in advanced NETs.
First Author: Jie Li
First Author: Sujana Movva
Poster
2020 ASCO Virtual Scientific Program
Health-related quality-of-life results from SANET-ep: A phase III study of surufatinib versus placebo for advanced extrapancreatic neuroendocrine tumors.
First Author: Chunmei Bai